Teva initiates phase III trial of long-acting schizophrenia injection
Using technology from Medincell, the Israeli generic drugmaker will investigate the long-acting antipsychotic potential of olanzapine, which was originally launched by Eli Lilly years ago, in a phase III study.
by ulrich quistgaard, translated by daniel pedersen
Israeli generic drugmaker Teva is attempting to develop the substance olanzapine into a long-acting schizophrenia treatment, improving upon the daily tablet administration now.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA rejects schizophrenia drug from Teva
For subscribers
Teva enters billion-dollar settlement in US opioid case
For subscribers
